HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease

Stem Cell Research & Therapy (Impact Factor: 4.63). 12/2013; 4 Suppl 1:S8. DOI: 10.1186/scrt369
Source: PubMed

ABSTRACT Our project team is developing an integrated microphysiological platform with functionally connected vascular, liver and cardiac microtissues derived from a single line of human pluripotent stem cells. The platform enables functional representation of human physiology in conjunction with real-time biological readouts (via imaging and homologous reporters for all three cell phenotypes) and compatibility with high-throughput/high-content analysis. In this paper, we summarize progress made over the first year of the grant.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the tremendous hurdles presented by the complexity of the liver's structure and function, advances in liver physiology, stem cell biology and reprogramming, and the engineering of tissues and devices are accelerating the development of cell-based therapies for treating liver disease and liver failure. This State of the Art Review discusses both the near- and long-term prospects for such cell-based therapies and the unique challenges for clinical translation.
    Science translational medicine 07/2014; 6(245):245sr2. DOI:10.1126/scitranslmed.3005975 · 14.41 Impact Factor

Full-text (3 Sources)

Available from
Dec 25, 2014